Nektar Therapeutics NKTR Free cash flow

Free cash flow at other companies

AmgenAMGN

$3.49B+82.6%

Regeneron PharmaceuticalsREGN

$572.8M-38.1%

ImmunityBio, Inc.IBRX

-$77.14M+11.4%

Artiva Biotherapeutics, Inc.ARTV

-$20.77M+13.6%

Vor BiopharmaVOR

-$38.29M-22.4%

Vera TherapeuticsVERA

-$106.52M-95.1%

FAQ

What is Nektar Therapeutics's free cash flow?

Nektar Therapeutics (NKTR) reported free cash flow of -$75.86M in Q2 2026.

How has Nektar Therapeutics's free cash flow changed year-over-year?

Nektar Therapeutics's free cash flow decreased by 65.7% year-over-year, from -$45.78M to -$75.86M.

What is the long-term trend for Nektar Therapeutics's free cash flow?

Over 4 years (2021 to 2025), Nektar Therapeutics's free cash flow has grown at a -16.4% compound annual growth rate (CAGR), from -$427.65M to -$208.68M.

What does free cash flow mean?

Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.